Previous 10 | Next 10 |
Mereo BioPharma (NASDAQ:MREO) reported results from a mid-stage study of its oral drug alvelestat to treat a lung condition. The phase 2 trial, dubbed ASTRAEUS, evaluated two different doses of alvelestat (high or low dose) or placebo in patients with severe alpha-1 antitrypsin defi...
Buying Penny Stocks on May 9th? Here’s What You Need to Know If you’re looking for penny stocks to buy, there are hundreds of options to choose from. And after last week’s very volatile trading, many investors are unenthused about the state of the stock market right...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips We’re starting off another week of trading with an overview of the biggest pre-market stock mover for Monday! Source: Eric Urquhart/Shutterstock.com News moving stocks this morning include clinical trial resu...
Statistically significant inhibition of blood neutrophil elastase activity of up to 90% in patients in both high and low dose alvelestat groups throughout the 12-week dosing period Statistically significant reductions in the biomarkers Aα-val 360 and desmosine at ...
LONDON and REDWOOD CITY, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced it will host a conference call ...
LONDON and REDWOOD CITY, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight...
Mereo BioPharma Group press release (NASDAQ:MREO): FY GAAP EPS of -£0.05. Revenue of £36.46M. Cash and short-term deposits totaled £94.3 million at December 31, 2021. For further details see: Mereo BioPharma Group GAAP EPS of -£0.05, revenue of ...
LONDON and REDWOOD CITY, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced financial results for the ye...
Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...
Gainers: Adagio Therapeutics (ADGI) +47%. Insignia Systems (ISIG) +26%. Romeo Power (RMO) +24%. Vir Biotechnology (VIR) +20%. TMC the metals company (TMC) +19%. Arhaus (ARHS) +19%. Ambac Financial Group (AMBC) +18%. Pear Therapeutics (PEAR) +17%. Vyant Bio (VYNT) +16%. Sportradar (SRAD) +16%....
News, Short Squeeze, Breakout and More Instantly...
Mereo BioPharma Group Company Name:
MREO Stock Symbol:
NASDAQ Market:
Mereo BioPharma Group Website:
2024-06-20 09:00:06 ET Joseph Schwartz from Leerink Partners issued a price target of $8.00 for MREO on 2024-06-20 07:21:00. The adjusted price target was set to $8.00. At the time of the announcement, MREO was trading at $3.98. The overall price target consensus is at $...
2024-06-14 10:45:03 ET Cleanspark Inc (CLSK) CLSK is trading UP for the last 5 days, and it at trading at $18.30 with volume of 12,068,034 and a one day change of $0.33 (1.84%). Cleanspark Inc has a 52-week low of 3.38 and a 52-week high of $24.72. The business's 50-day moving avera...
LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the pricing of an underwritten offering of 12,531,300 of its American Dep...